176 related articles for article (PubMed ID: 27428436)
1. One of the immune activation profiles observed in HIV-1-infected adults with suppressed viremia is linked to metabolic syndrome: The ACTIVIH study.
Psomas C; Younas M; Reynes C; Cezar R; Portalès P; Tuaillon E; Guigues A; Merle C; Atoui N; Fernandez C; Le Moing V; Barbuat C; Marin G; Nagot N; Sotto A; Eliaou JF; Sabatier R; Reynes J; Corbeau P
EBioMedicine; 2016 Jun; 8():265-276. PubMed ID: 27428436
[TBL] [Abstract][Full Text] [Related]
2. Residual Viremia Is Linked to a Specific Immune Activation Profile in HIV-1-Infected Adults Under Efficient Antiretroviral Therapy.
Younas M; Psomas C; Reynes C; Cezar R; Kundura L; Portalès P; Merle C; Atoui N; Fernandez C; Le Moing V; Barbuat C; Sotto A; Sabatier R; Winter A; Fabbro P; Vincent T; Reynes J; Corbeau P
Front Immunol; 2021; 12():663843. PubMed ID: 33859653
[TBL] [Abstract][Full Text] [Related]
3. Microbial Translocation Is Linked to a Specific Immune Activation Profile in HIV-1-Infected Adults With Suppressed Viremia.
Younas M; Psomas C; Reynes C; Cezar R; Kundura L; Portales P; Merle C; Atoui N; Fernandez C; Le Moing V; Barbuat C; Moranne O; Sotto A; Sabatier R; Fabbro P; Vincent T; Dunyach-Remy C; Winter A; Reynes J; Lavigne JP; Corbeau P
Front Immunol; 2019; 10():2185. PubMed ID: 31572392
[TBL] [Abstract][Full Text] [Related]
4. Immune activation in the course of HIV-1 infection: Causes, phenotypes and persistence under therapy.
Younas M; Psomas C; Reynes J; Corbeau P
HIV Med; 2016 Feb; 17(2):89-105. PubMed ID: 26452565
[TBL] [Abstract][Full Text] [Related]
5. Increased Natural Killer Cell Activation in HIV-Infected Immunologic Non-Responders Correlates with CD4+ T Cell Recovery after Antiretroviral Therapy and Viral Suppression.
Luo Z; Li Z; Martin L; Hu Z; Wu H; Wan Z; Kilby M; Heath SL; Huang L; Jiang W
PLoS One; 2017; 12(1):e0167640. PubMed ID: 28076376
[TBL] [Abstract][Full Text] [Related]
6. HCV viraemia associates with NK cell activation and dysfunction in antiretroviral therapy-treated HIV/HCV-co-infected subjects.
Papasavvas E; Azzoni L; Yin X; Liu Q; Joseph J; Mackiewicz A; Ross B; Lynn KM; Jacobson JM; Mounzer K; Kostman JR; Montaner LJ
J Viral Hepat; 2017 Oct; 24(10):865-876. PubMed ID: 28419653
[TBL] [Abstract][Full Text] [Related]
7. Immunologic features of HIV-1-infected women on HAART at delivery.
Ono E; Dos Santos AM; Machado DM; Succi RC; Amed AM; Salomão R; Kallás EG; de Moraes-Pinto MI
Cytometry B Clin Cytom; 2008 Jul; 74(4):236-43. PubMed ID: 18393385
[TBL] [Abstract][Full Text] [Related]
8. Defective IL-2 production by HIV-1-specific CD4 and CD8 T cells in an adolescent/young adult cohort.
Kapogiannis BG; Henderson SL; Nigam P; Sharma S; Chennareddi L; Herndon JG; Robinson HL; Amara RR
AIDS Res Hum Retroviruses; 2006 Mar; 22(3):272-82. PubMed ID: 16545014
[TBL] [Abstract][Full Text] [Related]
9. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI
Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945
[TBL] [Abstract][Full Text] [Related]
10. Dominant enrichment of phenotypically activated CD38(+) HLA-DR(+) CD8(+) T cells, rather than CD38(+) HLA-DR(+) CD4(+) T cells, in HIV/HCV coinfected patients on antiretroviral therapy.
d'Ettorre G; Ceccarelli G; Serafino S; Giustini N; Cavallari EN; Bianchi L; Pavone P; Bellelli V; Turriziani O; Antonelli G; Stroffolini T; Vullo V
J Med Virol; 2016 Aug; 88(8):1347-56. PubMed ID: 26765625
[TBL] [Abstract][Full Text] [Related]
11. Anti-Tat immunity defines CD4
Tripiciano A; Picconi O; Moretti S; Sgadari C; Cafaro A; Francavilla V; Arancio A; Paniccia G; Campagna M; Pavone-Cossut MR; Sighinolfi L; Latini A; Mercurio VS; Pietro MD; Castelli F; Saracino A; Mussini C; Perri GD; Galli M; Nozza S; Ensoli F; Monini P; Ensoli B
EBioMedicine; 2021 Apr; 66():103306. PubMed ID: 33839064
[TBL] [Abstract][Full Text] [Related]
12. The independent effect of drug resistance on T cell activation in HIV infection.
Hunt PW; Deeks SG; Bangsberg DR; Moss A; Sinclair E; Liegler T; Bates M; Tsao G; Lampiris H; Hoh R; Martin JN
AIDS; 2006 Mar; 20(5):691-9. PubMed ID: 16514299
[TBL] [Abstract][Full Text] [Related]
13. Antiretroviral therapy in HIV-1-infected individuals with CD4 count below 100 cells/mm3 results in differential recovery of monocyte activation.
Patro SC; Azzoni L; Joseph J; Fair MG; Sierra-Madero JG; Rassool MS; Sanne I; Montaner LJ
J Leukoc Biol; 2016 Jul; 100(1):223-31. PubMed ID: 26609048
[TBL] [Abstract][Full Text] [Related]
14. Increased soluble Fas in HIV-infected hemophilia patients with CD4+ and CD8+ cell count increases and viral load and immune complex decreases.
Daniel V; Süsal C; Weimer R; Zimmermann R; Huth-Kühne A; Opelz G
AIDS Res Hum Retroviruses; 2001 Mar; 17(4):329-35. PubMed ID: 11242519
[TBL] [Abstract][Full Text] [Related]
15. Increase in frequencies of circulating Th-17 cells correlates with microbial translocation, immune activation and exhaustion in HIV-1 infected patients with poor CD4 T-cell reconstitution.
Valiathan R; Asthana D
Immunobiology; 2016 May; 221(5):670-8. PubMed ID: 26817581
[TBL] [Abstract][Full Text] [Related]
16. Activation of NK cells is associated with HIV-1 disease progression.
Kuri-Cervantes L; de Oca GS; Avila-Ríos S; Hernández-Juan R; Reyes-Terán G
J Leukoc Biol; 2014 Jul; 96(1):7-16. PubMed ID: 24399837
[TBL] [Abstract][Full Text] [Related]
17. Baseline viral load and immune activation determine the extent of reconstitution of innate immune effectors in HIV-1-infected subjects undergoing antiretroviral treatment.
Chehimi J; Azzoni L; Farabaugh M; Creer SA; Tomescu C; Hancock A; Mackiewicz A; D'Alessandro L; Ghanekar S; Foulkes AS; Mounzer K; Kostman J; Montaner LJ
J Immunol; 2007 Aug; 179(4):2642-50. PubMed ID: 17675528
[TBL] [Abstract][Full Text] [Related]
18. Productive human immunodeficiency virus type 1 infection in peripheral blood predominantly takes place in CD4/CD8 double-negative T lymphocytes.
Kaiser P; Joos B; Niederöst B; Weber R; Günthard HF; Fischer M
J Virol; 2007 Sep; 81(18):9693-706. PubMed ID: 17609262
[TBL] [Abstract][Full Text] [Related]
19. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
[TBL] [Abstract][Full Text] [Related]
20. Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery.
Cillo AR; Hilldorfer BB; Lalama CM; McKinnon JE; Coombs RW; Tenorio AR; Fox L; Gandhi RT; Ribaudo H; Currier JS; Gulick RM; Wilkin TJ; Mellors JW
AIDS; 2015 Oct; 29(16):2121-9. PubMed ID: 26544577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
